Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395930 | 0.99 | CACNA1H (0.76) | CACNA1HALDH1A1LMNARXFP1L3MBTL3 | |
| SCHEMBL400086 | 0.89 | CACNA1H (0.94) | CACNA1HALDH1A1LMNARXFP1L3MBTL1 | |
| SCHEMBL400191 | 0.87 | CACNA1H (1.00) | CACNA1HALDH1A1LMNARXFP1L3MBTL1 | |
| SCHEMBL395430 | 0.87 | CACNA1H (1.00) | CACNA1HALDH1A1LMNARXFP1L3MBTL1 | |
| SCHEMBL399014 | 0.85 | L3MBTL3 (0.64) | CACNA1HALDH1A1LMNAL3MBTL3L3MBTL1 | |
| SCHEMBL399296 | 0.85 | L3MBTL1 (0.77) | CACNA1HALDH1A1L3MBTL3L3MBTL1TDP1 | |
| SCHEMBL399293 | 0.84 | POLB (0.74) | CACNA1HALDH1A1LMNAL3MBTL3L3MBTL1 | |
| SCHEMBL398558 | 0.84 | L3MBTL1 (0.75) | CACNA1HALDH1A1L3MBTL3L3MBTL1TDP1 | |
| SCHEMBL398692 | 0.83 | POLB (0.72) | CACNA1HALDH1A1LMNAL3MBTL3L3MBTL1 | |
| SCHEMBL395364 | 0.81 | CACNA1H (0.88) | CACNA1HALDH1A1LMNARXFP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102282131-B | As the new benzsulfamide of calcium ion channel blockor | ABBVIE INC. (BS) | 2015-08-26 | — | — | CN | claimed |
| EP-2382191-B1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE BAHAMAS LTD (BS) | 2014-11-12 | — | — | EP | claimed |
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-08-15 | — | — | US | claimed |
| US-8404719-B2 | Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | claimed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | claimed |
| CN-102282131-B | As the new benzsulfamide of calcium ion channel blockor | ABBVIE INC. (BS) | 2015-08-26 | — | — | CN | disclosed |
| EP-2382191-B1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE BAHAMAS LTD (BS) | 2014-11-12 | — | — | EP | disclosed |
| US-8741899-B2 | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8404719-B2 | Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-8101614-B2 | Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | CACNA1H 13/4885ALDH1A1 1038/4885LMNA 868/4885 |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | CACNA1H 13/4885ALDH1A1 1038/4885LMNA 868/4885 |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | CACNA1H 13/4885ALDH1A1 1038/4885LMNA 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.